These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 429787)

  • 41. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older.
    Forrest BD; Steele AD; Hiemstra L; Rappaport R; Ambrose CS; Gruber WC
    Vaccine; 2011 May; 29(20):3633-9. PubMed ID: 21440036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Characteristics of the immunological and protective effect in the simultaneous and separate use of live and killed influenza vaccines].
    Orlov VA; Zhilova GP; Smorodintsev AA; Kozhukhov VM; Ignat'eva GS
    Vopr Virusol; 1985; 30(3):280-5. PubMed ID: 4049837
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Challenge versus natural infection as an index or protection after influenza immunization.
    Donikian MA; McKee J; Greene LC
    Dev Biol Stand; 1977 Jun 1-3; 39():149-54. PubMed ID: 342306
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunogenicity and efficacy of the monovalent, trivalent and quadrivalent intranasal live attenuated influenza vaccines containing different pdmH1N1 strains.
    Yeolekar LR; Ganguly M; Tyagi P; Ingle NB; Stittelaar KJ; Waal L; Scorza FB; Mahmood K; Dhere RM
    Vaccine; 2018 Nov; 36(46):6944-6952. PubMed ID: 30322745
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults.
    Keitel WA; Couch RB; Quarles JM; Cate TR; Baxter B; Maassab HF
    J Infect Dis; 1993 Feb; 167(2):305-11. PubMed ID: 8421165
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home.
    Iorio AM; Neri M; Lepri E; Camilloni B; Basileo M; Sigismondi N; Fabiani C; Calzoletti L; Puzelli S; Donatelli I
    Vaccine; 2006 Nov; 24(44-46):6615-9. PubMed ID: 16828941
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epidemiological evaluation of the protection conferred by the Nivgrip vaccine against influenza caused by the A(H1N1) virus.
    Teodorovici G; Ivan A; Petrescu A; Mihail A; Cajal N
    Virologie; 1982; 33(4):279-82. PubMed ID: 7164342
    [No Abstract]   [Full Text] [Related]  

  • 49. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group.
    Gruber WC; Belshe RB; King JC; Treanor JJ; Piedra PA; Wright PF; Reed GW; Anderson E; Newman F
    J Infect Dis; 1996 Jun; 173(6):1313-9. PubMed ID: 8648202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the protective efficacies of the live vaccine RIT 4025 and an inactivated vaccine against a natural heterologous A/Victoria/3/75 infection.
    Delem A; Van Rensburg W; Flaskett I
    J Hyg (Lond); 1979 Oct; 83(2):221-9. PubMed ID: 385764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.
    Toback SL; Levin MJ; Block SL; Belshe RB; Ambrose CS; Falloon J
    Expert Rev Vaccines; 2012 Nov; 11(11):1293-303. PubMed ID: 23151111
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evolutionary pattern of reemerging influenza B/Victoria lineage viruses in São Paulo, Brazil, 1996-2012: Implications for vaccine composition strategy.
    Paiva TM; Benega MA; Silva DB; Santos KC; Cruz AS; Hortenci MF; Barbieri MT; Monteiro MM; Barbosa HA; Carvalhanas TR
    J Med Virol; 2013 Nov; 85(11):1983-9. PubMed ID: 23926069
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season.
    Petrie JG; Ohmit SE; Truscon R; Johnson E; Braun TM; Levine MZ; Eichelberger MC; Monto AS
    J Infect Dis; 2016 Oct; 214(8):1142-9. PubMed ID: 27095420
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home.
    Camilloni B; Neri M; Lepri E; Basileo M; Sigismondi N; Puzelli S; Donatelli I; Iorio AM
    Vaccine; 2010 Nov; 28(47):7536-41. PubMed ID: 20846530
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine.
    Belshe R; Lee MS; Walker RE; Stoddard J; Mendelman PM
    Expert Rev Vaccines; 2004 Dec; 3(6):643-54. PubMed ID: 15606348
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains.
    Luytjes W; Enouf V; Schipper M; Gijzen K; Liu WM; van der Lubben M; Meijer A; van der Werf S; Soethout EC
    Vaccine; 2012 Jul; 30(35):5262-9. PubMed ID: 22691431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of sequential annual vaccination with inactivated influenza virus vaccine.
    Keitel WA; Cate TR; Couch RB
    Am J Epidemiol; 1988 Feb; 127(2):353-64. PubMed ID: 3337087
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influenza B virus vaccines in children and adults: adverse reactions, immune response, and observations in the field.
    Foy HM; Cooney MK; Allan ID; Frost F; Blumhagen JM; Fox JP
    J Infect Dis; 1981 May; 143(5):700-6. PubMed ID: 7240807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
    Block SL; Yogev R; Hayden FG; Ambrose CS; Zeng W; Walker RE
    Vaccine; 2008 Sep; 26(38):4940-6. PubMed ID: 18662737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Serological and clinical studies on an epidemic of influenza type B].
    Niwa A
    Nihon Ika Daigaku Zasshi; 1985 Apr; 52(2):123-30. PubMed ID: 3998076
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.